Rosuvastatin Calcium is an HMG-CoA reductase inhibitor (statin) indicated for hyperlipidemia, hypertriglyceridemia and prevention of cardiovascular disease. We supply it to US manufacturers of tablets and capsules.
Data from PubChem (CID 5282455) and FDA’s substance registry
CAS number
147098-20-2
Molecular formula
C44H54CaF2N6O12S2
Molecular weight
1001.1g/mol
FDA UNII
IUPAC name
calcium bis((E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate)
InChIKey
LALFOYNTGMUKGG-BGRFNVSISA-L
- Appearance
- White to almost white, hygroscopic powder.
- Solubility
- Slightly soluble in water and freely soluble in methylene chloride.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Amorphous and hygroscopic, and it degrades with light, heat and moisture. Ask how the source packs and ships it, and what water content limit it releases to.
On the US market
- Reference product
- CrestorNDA 021366
- Approved ANDAs
- 19 with a marketed product
- Approved forms and strengths
- Tablet 5 mg, 10 mg, 20 mg, 40 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. Strengths of salt forms are stated as the active moiety. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com